🇺🇸#us #earningsseason #report #stocks #markets
FactSet: overall, 50% of the companies in the SP500 have reported actual results for Q4 2022 to date. Of these companies, 70% have reported actual EPS above estimates, but below the 5-year average of 77% and below the 10-year average of 73%
FactSet: overall, 50% of the companies in the SP500 have reported actual results for Q4 2022 to date. Of these companies, 70% have reported actual EPS above estimates, but below the 5-year average of 77% and below the 10-year average of 73%
🇺🇸#WU #report #watchlist
Western Union:
- Q4 Non-GAAP EPS of $0.32 misses by $0.03
- Revenue of $1.09B (-14.8% Y/Y)
#dividends approves Q1 quarterly dividend of $0.235
Western Union:
- Q4 Non-GAAP EPS of $0.32 misses by $0.03
- Revenue of $1.09B (-14.8% Y/Y)
#dividends approves Q1 quarterly dividend of $0.235
🇺🇸#MAC #report #watchlist
Macerich:
- Q4 FFO of $0.53 beats by $0.01
- Revenue of $228.22M (-0.5% Y/Y)
- Portfolio occupancy as of Dec. 31, 2022 = 92.6%
FY23 Guidance: FFO of $1.75-$1.85 vs $1.81 consensus
Macerich:
- Q4 FFO of $0.53 beats by $0.01
- Revenue of $228.22M (-0.5% Y/Y)
- Portfolio occupancy as of Dec. 31, 2022 = 92.6%
FY23 Guidance: FFO of $1.75-$1.85 vs $1.81 consensus
🇺🇸#GNW #report #watchlist
Genworth Financial:
- Q4 Non-GAAP EPS of $0.33 beats by $0.10
- Revenue of $1.9B (+9.2% Y/Y)
Continued progress against long-term care insurance multi-year rate action plan, with approximately $23.5 billion net present value from achieved LTC rate actions since 2012
Genworth Financial:
- Q4 Non-GAAP EPS of $0.33 beats by $0.10
- Revenue of $1.9B (+9.2% Y/Y)
Continued progress against long-term care insurance multi-year rate action plan, with approximately $23.5 billion net present value from achieved LTC rate actions since 2012
🇺🇸#OMF #report #watchlist
OneMain Holdings:
- Q4 Non-GAAP EPS of $1.56 beats by $0.05
- Revenue of $1.06B (+3.9% Y/Y) in-line
- 4Q 2022 Managed receivables of $20.8B
#dividends declares $1.00/share quarterly dividend
OneMain Holdings:
- Q4 Non-GAAP EPS of $1.56 beats by $0.05
- Revenue of $1.06B (+3.9% Y/Y) in-line
- 4Q 2022 Managed receivables of $20.8B
#dividends declares $1.00/share quarterly dividend
⚡️🇺🇸#TEVA #report #watchlist
Teva Pharmaceutical:
- Q4 Non-GAAP EPS of $0.71 in-line
- Revenue of $3.9B (-4.9% Y/Y) misses by $10M
2023 business outlook: Revenues are expected to be $14.8 - $15.4 billion vs. consensus of $15.19B; Adjusted EBITDA of $4.5 - $4.9 billion; Non-GAAP diluted EPS is expected to be $2.25 - $2.55 vs. consensus of $2.52; Free cash flow is expected to be $1.7 - $2.1 billion.
Teva Pharmaceutical:
- Q4 Non-GAAP EPS of $0.71 in-line
- Revenue of $3.9B (-4.9% Y/Y) misses by $10M
2023 business outlook: Revenues are expected to be $14.8 - $15.4 billion vs. consensus of $15.19B; Adjusted EBITDA of $4.5 - $4.9 billion; Non-GAAP diluted EPS is expected to be $2.25 - $2.55 vs. consensus of $2.52; Free cash flow is expected to be $1.7 - $2.1 billion.
🇺🇸#NLY #report #watchlist
Annaly Capital Management:
- Q4 Non-GAAP EPS of $0.89 beats by $0.01
- Q4 GAAP EPS -$1.96 per average common share
- FY2022 EPS $3.93 per average common share
#dividends declared dividend of $0.88 per share
Annaly Capital Management:
- Q4 Non-GAAP EPS of $0.89 beats by $0.01
- Q4 GAAP EPS -$1.96 per average common share
- FY2022 EPS $3.93 per average common share
#dividends declared dividend of $0.88 per share
🇺🇸#CXW #report #watchlist
Corecivic:
- Q4 FFO of $0.42 beats by $0.09
- Revenue of $471.43M (-0.1% Y/Y)
2023 Outlook: Net income $58.0 million to $75.0 million, FFO per diluted share $1.35 to $1.50, Diluted EPS $0.50 to $0.65, EBITDA $298.5 million to $313.5 million, during 2023, expect to invest $64.0 million to $67.0 million in CAPEX
Corecivic:
- Q4 FFO of $0.42 beats by $0.09
- Revenue of $471.43M (-0.1% Y/Y)
2023 Outlook: Net income $58.0 million to $75.0 million, FFO per diluted share $1.35 to $1.50, Diluted EPS $0.50 to $0.65, EBITDA $298.5 million to $313.5 million, during 2023, expect to invest $64.0 million to $67.0 million in CAPEX